Inserra F

Language: Spanish
References: 8
Page: 169-171
PDF size: 137.38 Kb.

Text Extraction

No abstract.

REFERENCES

1. Kidney Disease: Improving Global Outcomes(KDIGO) CKD Work Group. KDIGO 2024Clinical Practice Guideline for the Evaluation andManagement of Chronic Kidney Disease. Kidney Int.

2. 2024;105(4S):S117-S314.

3. Murakami T, Iwamoto T, Yasuda G, Taniguchi M,Fujiwara A, Hirawa N, Umemura S. Role of reninangiotensinsystem inhibitors in retardation ofprogression of end-stage renal failure: a retrospectivestudy. Clin Exp Nephrol. 2016;20:603-610.

4. Voskamp PWM, Dekker FW, van Diepen M,Hoogeveen EK; PREPARE-2 Study Group. Effectof dual compared to no or single renin-angiotensinsystem blockade on risk of renal replacement therapyor death in predialysis patients: PREPARE-2 study. JAm Soc Hypertens. 2017;11:635-643.

5. Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N,Brettell E, et al; STOP ACEi Trial Investigators. Renin-Angiotensin System Inhibition in Advanced ChronicKidney Disease. N Engl J Med. 2022;387:2021-2032

6. Lee JH, Kwon YE, Park JT, Lee MJ, Oh HJ, Han SH,et al. The effect of renin-angiotensin system blockadeon renal protection in chronic kidney disease patientswith hyperkalemia. J Renin Angiotensin AldosteroneSyst. 2014;15:491-497.

7. Ku E, McCulloch CE, Vittinghoff E, Lin F, JohansenKL. Use of Antihypertensive Agents and Associationwith Risk of Adverse Outcomes in Chronic KidneyDisease: Focus on Angiotensin-Converting EnzymeInhibitors and Angiotensin Receptor Blockers. J AmHeart Assoc. 2018 Oct 2;7(19):e009992.

8. Shulman R, Yang W, Cohen DL, Reese PP, Cohen JB;CRIC Study Investigators. Cardiac Effects of Renin-Angiotensin System Inhibitors in NonproteinuricCKD. Hypertension. 2024 Aug 1. doi: 10.1161/HYPERTENSIONAHA.124.23184.